Giroctocogene fitelparvovec is an experimental gene therapy for hemophilia A via a recombinant adeno-associated virus serotype 6-based vector. From Wikipedia
Sangamo regains rights to its hemophilia A gene therapy but faces uncertainty after Pfizer's withdrawal despite strong Phase III trial results.
